Foot orthoses and footwear for the management of patellofemoral osteoarthritis: a pilot randomized trial.
Determine the feasibility of a full-scale randomised controlled trial (RCT) comparing foot orthoses and footwear to footwear alone in people with patellofemoral osteoarthritis (PFOA). This four-month, parallel, two-arm pilot trial took place in Brisbane, Queensland and Hobart, Tasmania (August 2014 to October 2016). Forty-six people with PFOA were randomized by concealed allocation to: (i) foot orthoses plus prescribed footwear (n=24); or (ii) prescribed footwear (n=22). Study feasibility was the primary outcome (e.g. recruitment rate, adherence, adverse events, drop-out rate). Secondary outcomes included patient-reported outcome measures of pain, function and quality of life. Effect sizes with 95% confidence intervals were calculated at four months (primary end-point) (standardized mean differences (SMD) for between-group effects; standardized response means (SRM) for within-group effects). From 782 volunteers, 47 were eligible (6%) and 46 participated. One participant withdrew (2%) and 1 (2%) was lost to follow-up. Intervention adherence was high for both groups (9-10 hours wear per day). No serious adverse events were reported. More than 80% of questionnaires were completed at 4 months. Between-group effect sizes for patient-reported outcome measures were typically small, while moderate to large within-group response effects were observed in both groups. A full-scale RCT for PFOA is feasible with modifications to eligibility criteria. However, our observed small between-group effect sizes, combined with moderate to large within-group responses for both interventions, indicate that a full-scale trial is unlikely to find clinically meaningful differences. Secondary outcomes suggest that both interventions can be recommended for people with PFOA.